Pregled bibliografske jedinice broj: 119565
P53 and BCL-2 expression in extrahepatic bile duct carcinomas
P53 and BCL-2 expression in extrahepatic bile duct carcinomas // The 10th Ljudevit Jurak International symposium on comparative pathology : book of abstracts / Talan Hranilović, Jasna ; Krušlin, Božo (ur.).
Zagreb: Acta Medica Croatica, 1999. (poster, domaća recenzija, sažetak, stručni)
CROSBI ID: 119565 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
P53 and BCL-2 expression in extrahepatic bile duct carcinomas
Autori
Kopjar, A. ; Vučić, Majda ; Šeni, B. ; Hochstaadter, H. ; Čupić, Hrvoje ; Belicza, Mladen ; Krušlin, Božo
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
The 10th Ljudevit Jurak International symposium on comparative pathology : book of abstracts
/ Talan Hranilović, Jasna ; Krušlin, Božo - Zagreb : Acta Medica Croatica, 1999
ISBN
9539728223
Skup
Ljudevit Jurak International symposium on comparative pathology (10 ; 1999)
Mjesto i datum
Zagreb, Hrvatska, 04.06.1999. - 05.06.1999
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
P53; BCL-2; extrahepatic bile duct carcinomas
Sažetak
The aim of the present study was to analyse the expression p53 and bcl-2 in the extrahepatic bilc duct carcinomas (EHBDC). We analysed tumour 13 patients with EHBDC's diagnosed at "Sestre milosrdnice" University Hospital in the 1990-1996 period. There were 10 female and 3 male patients ranging in age from 56-94 years. In 8 patients only palliative treatments was performed. Five patients underwent surgical resection. Histologic analysis revealed adenocarcinoma in all cases. Formalin fixed, paraffin embedded tumour tissue of these five patients was cut at 5 mm, deparaffinized, and stained with an antibody to p53 and bcl-2 (Dako, Denmark). Alkaline phosphatase/antialkaline phosphatase method was used. The intensity of immunostaining was graded semiquantitively and designated with (-) for no staining, (+) for 10% positive cells, (++) for 25% positive cells and (+++) for more than 25% positive cells. Histopathologic examination showed p53 expression in all cases: in 2 tumours the reaction was weakly positive (+), and in 3 tumours strongly positive (+++). We found weakly positive immunostaining for bcl-2 in 2 tumours, moderately positive in one tumour and strongly positive in 2 tumours (Table). We conclude that EHBDC's are uncommon tumours and the results of tretment at present are rather poor. It seems that p53 and bcl-2 are present EHBDC indicating their possible role in the development of these tumours. Assessmrnt of clinical and pathological impact of these genes on EHBDC requires evaluation in larger studies.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
